University of Vermont

The University of Vermont Cancer Center

trials_genito.html

Genito-Urinary Cancer Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on genito-urinary cancer research.

Status: Active - Recruiting
Study Title:
Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
Purpose: This randomized phase III trial is studying docetaxel and leuprolide or goserelin to see how well they work when given before surgery compared with surgery alone in treating patients with high-risk localized prostate cancer.
ClinicalTrials.gov Identifier: NCT00430183
Primary/Site/Co Investigator: Steven Ades, MD
Contact: Deb McAdoo (802) 656-9113
Information: http://www.clinicaltrials.gov/ct2/show/NCT00430183?term=CALGB+90203&rank=1
Institution Number: 95-106 CALGB 90203
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
Purpose: This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer.
ClinicalTrials.gov Identifier: NCT00567580
Primary/Site/Co Investigator: H. James Wallace, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://www.clinicaltrials.gov/ct2/show/NCT00567580?term=RTOG+0534&rank=1
Institution Number: 97-7 RTOG 05-34
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
CALGB 90601 - A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab(IND#7921, NSC #704865) to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Purpose: This randomized phase III trial is studying gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride, cisplatin, and placebo in treating patients with advanced urinary tract cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether gemcitabine hydrochloride and cisplatin are more effective when given together with or without bevacizumab in treating patients with urinary tract cancer
ClinicalTrials.gov Identifier: NCT00942331
Primary/Site/Co Investigator: Steven Ades, MD
Contact: Deb McAdoo (802) 656-9113
Information: http://www.clinicaltrials.gov/ct2/show/NCT00942331?term=CALGB+90601&rank=1
Institution Number: M11-084
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
CALGB 70807 - The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
Purpose: This randomized clinical trial is studying how well diet works in altering disease progression in patients with prostate cancer on active surveillance.
ClinicalTrials.gov Identifier: NCT01238172
Primary/Site/Co Investigator: Scott D. Perrapato, DO
Contact: Deb McAdoo (802) 656-9113
Information: http://www.clinicaltrials.gov/ct2/show/NCT01238172?term=CALGB+70807&rank=1
Institution Number: M11-157
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
RTOG 0924 – Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate  or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Purpose: The purpose of this study is to compare the effects, both good and bad, of two different radiation therapy treatment plans when given in conjunction with hormone therapy (androgen deprivation). This study is designed to help determine if treating a wider area with a higher dose of radiation will help reduce the risk of your disease worsening.  In addition this study is exploring whether there is any benefit to giving extended hormone therapy (longer than 6 months). 
ClinicalTrials.gov Identifier: NCT01368588
Primary/Site/Co Investigator: H. James Wallace, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://www.clinicaltrials.gov/ct2/show/NCT01368588?term=RTOG+0924&rank=1
Institution Number: CHRMS M12-222, RTOG 0924
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: RTOG 1115 – Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
Purpose: One of the common treatments for men with high risk prostate cancer includes radiation therapy and androgen deprivation with an LHRH agonist and antiandrogen (commonly called “hormone therapy”). The purpose of this study is to compare the effects of standard hormone therapy and radiation therapy with standard hormone therapy plus TAK-700 and radiation therapy on you and your prostate cancer to find out which is better. This study is testing if the combination of 3 drugs (LHRH agnonist, antiandrogen and TAK-700) further suppresses the action of testosterone and leads to an improved chance to cure your prostate cancer
ClinicalTrials.gov Identifier: NCT01546987
Primary/Site/Co Investigator: H. James Wallace, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://clinicaltrials.gov/ct2/show/NCT01546987?term=RTOG+1115&rank=1
Institution Number: CHRMS M14-004 / RTOG 1115
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: A031201 - Phase III Trial of Enzalutamide (NSC #766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Purpose: This randomized phase III trial studies enzalutatmide to see how well it works compared to enzalutatmide, abiraterone acetate, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutatmide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
ClinicalTrials.gov Identifier: NCT01949337
Primary/Site/Co Investigator: Steve Ades, MD
Contact: Deb McAdoo (802) 656-9113
Information: http://www.clinicaltrials.gov/ct2/show/NCT01949337?term=NCT01949337&rank=1
Institution Number: CHRMS 15-020 / A031201
Protocol Research Type: Cooperative Group

Last modified December 09 2014 04:17 PM